Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions

Core Insights - Labcorp has expanded its precision oncology portfolio with the introduction of Labcorp Plasma Detect for assessing recurrence risk in stage III colon cancer patients and the PGDx elio plasma focus Dx liquid biopsy test for targeted treatment selection [1][2] Group 1: Labcorp Plasma Detect - Labcorp Plasma Detect is a blood-based test utilizing whole-genome sequencing (WGS) to detect circulating tumor DNA (ctDNA), which indicates the presence of molecular residual disease (MRD) [3] - The test aims to identify patients at higher risk of recurrence, as stage III colon cancer has a nearly 30% recurrence rate within five years [3] - Labcorp Plasma Detect will initially be offered through an Early Experience Program, with plans for broader availability [4] Group 2: PGDx elio plasma focus Dx - PGDx elio plasma focus Dx is the first kitted pan-solid tumor liquid biopsy test authorized by the FDA, designed to aid oncologists in targeted treatment selection from a simple blood draw [5] - The test combines a WGS approach with proprietary bioinformatics, achieving a limit of detection (LOD95) of 0.005% for ctDNA [5] - Results are available approximately 14 days after the initial sample is received, with a seven-day turnaround for subsequent monitoring [5] Group 3: Clinical Studies and Implementation - Labcorp Plasma Detect is currently being evaluated in over 10 clinical studies in the U.S. and internationally to assess MRD across various cancer types [6] - The kitted model of PGDx elio plasma focus Dx allows clinical laboratories to maintain control over patient specimens and data, facilitating rapid implementation with only on-site verification required [6] - The test provides actionable findings within a 4-to-5-day turnaround time, enhancing the efficiency of genomic profiling workflows [6][7] Group 4: Industry Engagement - Labcorp will present key studies related to Labcorp Plasma Detect and PGDx elio plasma focus Dx at the AACR 2025 Annual Meeting [8] - The company emphasizes its commitment to transforming cancer diagnostics and improving patient outcomes through innovative solutions [2]